NFKB1 and B-cell chronic lymphocytic leukemia: CTAR1 activates the p50/p50, the p50/p52, and the p52/p65 dimers, but CTAR2 only activates the p52/p65 dimer [56], which initially inhibits transcription but can acquire the transcriptional activity after combining with B-Cell Chronic Lymphocytic Leukaemia/Lymphoma-3 (Bcl-3) [57].